Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul C Moser

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Behavioral indices in antipsychotic drug discoveryRoger D Porsolt, Paul C Moser, Vincent Castagné
Advances in Pharmacology (San Diego, Calif.)|March 17, 2010
Preclinical behavioral models for predicting antipsychotic activityVincent Castagné, Paul C Moser, Roger D Porsolt
Journal of Pharmacological and Toxicological Methods|March 17, 2011
Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studiesJames J Lynch, Vincent Castagné, Paul C Moser, et al.
European Journal of Pharmacology|October 16, 2020
Pharmacology profile of F17464, a dopamine D<sub>3</sub> receptor preferential antagonistCristina Cosi, Jean-Claude Martel, Agnès L Auclair, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing propertiesPaul C Moser, Olivier E Bergis, Samir Jegham, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Behavioral indices in antipsychotic drug discoveryRoger D Porsolt, Paul C Moser, Vincent Castagné
Advances in Pharmacology (San Diego, Calif.)|March 17, 2010
Preclinical behavioral models for predicting antipsychotic activityVincent Castagné, Paul C Moser, Roger D Porsolt
Journal of Pharmacological and Toxicological Methods|March 17, 2011
Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studiesJames J Lynch, Vincent Castagné, Paul C Moser, et al.
European Journal of Pharmacology|October 16, 2020
Pharmacology profile of F17464, a dopamine D<sub>3</sub> receptor preferential antagonistCristina Cosi, Jean-Claude Martel, Agnès L Auclair, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing propertiesPaul C Moser, Olivier E Bergis, Samir Jegham, et al.
Pageof 1